September 2006. Volume 2. Number 3

Long-acting β-agonists may increase the risk for severe asthma exacerbations and asthma-related deaths, if they are not combined always with inhaled corticosteroids

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Salpeter S, Buckley NS, Ormiston TM, MD, Salpeter EE. Meta-Analysis: Meta-analysis: effect of long-acting-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med. 2006;144:904-12
Reviewers: Puebla Molina SF1, Modesto i Alapont V2.
1Departamento de Pediatrí­a Clí­nica Alemana de Temuco. Magí­ster en Epidemiologí­a Clí­nica. CIGES y Departamentos de Pediatrí­a y Salud Pública. Universidad de la Frontera. Chile.
2 Unidad de Cuidados Intensivos Pediátricos. Hospital Infantil La Fe. Valencia. España.
Correspondence: Sergio Francisco Puebla Molina. Email: spuebla@ufro.cl
Reception date: 21/07/2006
Acceptance date: 30/07/2006
Publication date: 01/09/2006

Abstract

How to cite this article

Puebla Molina SF, Modesto i Alapont V. El uso de beta agonistas de acción prolongada puede aumentar las exacerbaciones de asma severa, así como las muertes asociadas a éstas, si no se asocian siempre a corticoides inhalados. Evid Pediatr. 2006;2:53.

AVC | Critically appraised articles

Salpeter S, Buckley NS, Ormiston TM, MD, Salpeter EE. Meta-Analysis: Meta-analysis: effect of long-acting-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med. 2006;144:904-12
Reviewers: Puebla Molina SF1, Modesto i Alapont V2.
1Departamento de Pediatrí­a Clí­nica Alemana de Temuco. Magí­ster en Epidemiologí­a Clí­nica. CIGES y Departamentos de Pediatrí­a y Salud Pública. Universidad de la Frontera. Chile.
2 Unidad de Cuidados Intensivos Pediátricos. Hospital Infantil La Fe. Valencia. España.
Correspondence: Sergio Francisco Puebla Molina. Email: spuebla@ufro.cl
Reception date: 21/07/2006
Acceptance date: 30/07/2006
Publication date: 01/09/2006

How to cite this article

Puebla Molina SF, Modesto i Alapont V. El uso de beta agonistas de acción prolongada puede aumentar las exacerbaciones de asma severa, así como las muertes asociadas a éstas, si no se asocian siempre a corticoides inhalados. Evid Pediatr. 2006;2:53.

References

  1. O’Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164:1392-7.
  2. Kraan J, Koeter GH, vd Mark TW, Sluiter HJ, de Vries K. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol. 1985;76:628-36.
  3. Hancox RJ, Cowan JO, Flannery EM, Herbison GP, McLachlan CR, Wong CS, et al. Randomised trial of an inhaled beta2 agonist, inhaled corticosteroid and their combination in the treatment of asthma. Thorax. 1999;54:482-7.
  4. Kalra S, Swystun VA, Bhagat R, Cockcroft DW. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest. 1996;109:953-6.
  5. Taylor DR, Hancox RJ. Interactions between corticosteroids and beta agonists. Thorax. 2000;55:595-602.
  6. U.S. Food and Drug Administration. FDA Public Health Advisory. Serevent, Advair, Foradil. 2005 [en línea][fecha de consulta: 19-VII-2006]. Disponible en: http://www.fda.gov/cder/drug/advisory/LABA.htm.
01/09/2006

Linked Comment